March 28, 2002
Arryx, Inc. Completes Second Round Funding
Arryx, Inc., a company that provides laser systems for the pharmaceutical
and biotech industries, announced that it has completed a $2.1 million
second round of funding. Investors include Draper Fisher Jurvetson
Fund VII, Fahnestock Venture Capital Fund, and ARCH Development
Fund.
Arryx's first product, the BioRyx® 200 system, is a breakthrough
tool for drug development and therapeutic research. The BioRyx®
200 system integrates Arryx's proprietary holographic optical trapping
(HOT) technology with easy-to-use software to provide for the first
time the ability to use hundreds of laser beams for manipulating
hundreds of microscopic objects independently and simultaneously
in three dimensions.
"We are excited about the far-reaching impact of the BioRyx®
200 system's applications in cancer, genetics, and cell reproduction
research. One such application, for high-throughput screening of
potential therapeutic compounds, can help to accelerate drug discovery
and development and at the same time decrease spending per compound,"
said Lewis Gruber, co-founder and CEO of Arryx, Inc. "This financing
will allow us to continue to develop new products that use our patented
HOT technology, including dynamically-reconfigurable biochips which
allow researchers to be more efficient by enabling them to continuously
conduct experiments on one chip, automated cell sorters, and purification
equipment."
